Cidara Therapeutics
CDTX
CDTX was delisted on the 6th of January, 2026.
63 hedge funds and large institutions have $48.5M invested in Cidara Therapeutics in 2020 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 22 increasing their positions, 17 reducing their positions, and 12 closing their positions.
29% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 17
0.35% less ownership
Funds ownership: 3.11% → 2.76% (-0.35%)
5% less funds holding
Funds holding: 66 → 63 (-3)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
25% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 12
36% less capital invested
Capital invested by funds: $76.2M → $48.5M (-$27.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$758K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$735K |
| 3 |
Millennium Management
New York
|
+$496K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$382K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$266K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Frazier Management
Seattle,
Washington
|
-$3.74M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$2.77M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.81M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$453K |
| 5 |
Goldman Sachs
New York
|
-$360K |
CDTX Hedge Fund Activity: Q4 2020 in Review
63 of the 5,675 institutional investors tracked by Wall St. Rank reported a position in Cidara Therapeutics (CDTX) for Q4 2020, worth a combined $48.5M — down 36% from $76.2M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of CDTX and 9 opened new positions — a net loss of 3 holders — while 17 trimmed existing stakes and 22 added.
The largest buyer was Renaissance Technologies, adding an estimated $758K. The largest seller was Frazier Management, exiting entirely with an estimated $3.74M sold.
- 63 institutional investors held Cidara Therapeutics (CDTX) as of Q4 2020, down from 66 in Q3 2020.
- Funds reported $48.5M of Cidara Therapeutics stock for Q4 2020, down 36% quarter-over-quarter.
- 9 funds opened new Cidara Therapeutics positions in Q4 2020 and 12 closed out, a net change of -3 holders.
- The largest Cidara Therapeutics buyer in Q4 2020 was Renaissance Technologies, an estimated $758K added.
- The largest Cidara Therapeutics seller in Q4 2020 was Frazier Management, an estimated $3.74M sold.
Based on aggregated 13F filings for Q4 2020.